Poor Sleep
Sanofi India Limited and Cipla Limited have announced an exclusive partnership for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium®, a leading brand in the anti-epileptic medication category.
While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.
Under the Yellow Ribbon Campaign conceptualized in 1998 by Dr S K Sarin with the…
In a written reply to a question in the Rajya Sabha, Union Health Minister J…
India achieved 48.7 per cent decline in annual new HIV infections and 81.4 per cent reduction in AIDS-related…
In a significant medical achievement, doctors at HCMCT Manipal Hospital Dwarka, New Delhi, successfully performed…
Preventive health checks play a crucial role in identifying pollution-related risks early, especially for smokers,…
The Winter Session of Parliament has begun from Monday with a packed legislative agenda, including…